The field of cancer care has evolved over the past 20 years with the development of more aggressive cancer screening programs, improvement in diagnostic testing and more effective treatment options, including the incorporation of novel targeted therapies. As a result, cancer death rates are gradually declining while cancer survivorship is steadily rising. However, these benefits are offset by long term adverse effects. Among them, cardiotoxicity is a leading cause for late morbidity and mortality. While conventional chemotherapy has been known for decades to induce detrimental effects on the heart and peripheral vasculature, the novel agents might also have harmful off-target consequences. Thus, there is an unmet need for intimate collaboration between cardiologists, oncologists and hemato-oncologists. Furthermore, accelerated research of tumor cellular signaling and genetics opens unlimited research interplays between these disciplines. This prompted the development of the new field of cardio-oncology.

We herein launch the second International Meeting in Cardio-oncology to be held on June 15-16, 2017 in Tel Aviv.

The main aims of this meeting are:

  • To establish and develop the field of cardio-oncology in Israel.
  • To bring together cardiologists, oncologists, hemato-oncologists and general practitioners from Israel and worldwide.
  • To bring together national and international medical and para-medical disciplines involved, including the fields of imaging, biomarkers and others.
  • To give stage for basic scientists and Pharma companies involved in the development of novel antineoplastic treatments with potential for off-target cardiovascular effects.
  • To contribute to the development of international recommendations and guidelines in the field.

The meeting agenda is developed by multidisciplinary faculty led by prominent Israeli experts, including cardiology team (Prof. Ran Kornowski), oncology team (Dr. Rinat Yerushalmi), hemato-oncology team (Prof. Pia Raanani) with Prof. Dan Gilon in charge of the scientific program. The meeting is held biennially. It includes international faculty and medical staff as well as scientists and Pharma who will share cutting edge developments in the field, aiming at the development and implementation of strategies for the prevention, early detection and management of cardio-oncology issues.

Dr. Zaza Iakobishvili, MD, PhD, FESC
Israel, Chair of the Meeting
Prof. Daniel Lenihan, MD, FACC
USA, International Co-Chair of the Meeting, President of International Cardio-oncology Society North America (ICOSNA)
Prof. Dan Gilon, MD, FESC, FACC
Israel, Chair of Scientific Committee